180 related articles for article (PubMed ID: 16545435)
1. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
Berntorp E; Abshire T;
Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
[TBL] [Abstract][Full Text] [Related]
2. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis and von Willebrand's disease (vWD).
Abshire TC
Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of prophylactic treatment in von Willebrand disease.
Lethagen S
Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
[TBL] [Abstract][Full Text] [Related]
5. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
8. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
10. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow.
Abshire T
Thromb Res; 2009 Nov; 124 Suppl 1():S15-9. PubMed ID: 19944256
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
12. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
13. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
14. Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States.
Sumner M; Williams J
Haemophilia; 2004 Jul; 10(4):360-6. PubMed ID: 15230950
[TBL] [Abstract][Full Text] [Related]
15. The role of prophylaxis in bleeding disorders.
Berntorp E; de Moerloose P; Ljung RC
Haemophilia; 2010 Jul; 16 Suppl 5():189-93. PubMed ID: 20590880
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
17. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.
Holm E; Carlsson KS; Lövdahl S; Lail AE; Abshire TC; Berntorp E
Haemophilia; 2018 Jul; 24(4):628-633. PubMed ID: 29626372
[TBL] [Abstract][Full Text] [Related]
18. Management of inherited von Willebrand disease in 2007.
Federici AB; Mannucci PM
Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
[TBL] [Abstract][Full Text] [Related]
19. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
Coppola A; Cimino E; Conca P; De Simone C; Tufano A; Tarantino G; Cerbone AM; Minno G
Haemophilia; 2006 Jan; 12(1):90-4. PubMed ID: 16409182
[TBL] [Abstract][Full Text] [Related]
20. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
